Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Barata

Showing results (171-180 of 203) with videos related to

Pageof 21
Sort By:
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 StudyEmmanuel S Antonarakis, Qing Cao, Victoria Catharine, et al.
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancerAmanda Broderick, Elizabeth Pan, Jinju Li, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
European Urology Oncology|February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Pageof 21

Showing results (171-180 of 203) with videos related to

Sort By:
Pageof 21
Journal of the National Cancer Institute|December 19, 2018
Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in OncologyBrian P Hobbs, Pedro C Barata, Yada Kanjanapan, et al.
Frontiers in Oncology|October 3, 2022
Genomic landscape of advanced prostate cancer patients with <i>BRCA1</i> versus <i>BRCA2</i> mutations as detected by comprehensive genomic profiling of cell-free DNAUmang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, et al.
The Journal of Clinical Investigation|July 15, 2024
Molecular analysis of primary and metastatic sites in patients with renal cell carcinomaShuchi Gulati, Pedro C Barata, Andrew Elliott, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2026
Carboplatin, Cabazitaxel and Abiraterone in High-Volume Metastatic Castration-Sensitive Prostate Cancer: The CASCARA Phase 2 StudyEmmanuel S Antonarakis, Qing Cao, Victoria Catharine, et al.
JCO Precision Oncology|August 23, 2024
DNA-Damaging Therapies in Patients With Prostate Cancer and Pathogenic Alterations in Homologous Recombination Repair GenesLaura S Graham, Nicholas C Henderson, Olesia Kellezi, et al.
Prostate Cancer and Prostatic Diseases|July 17, 2024
Clinical implications of Wnt pathway genetic alterations in men with advanced prostate cancerAmanda Broderick, Elizabeth Pan, Jinju Li, et al.
Prostate Cancer and Prostatic Diseases|February 22, 2024
Clinical implications of AR alterations in advanced prostate cancer: a multi-institutional collaborationZeynep B Zengin, Nicholas C Henderson, Joseph J Park, et al.
The Prostate|November 16, 2022
Differential responses to taxanes and PARP inhibitors in ATM- versus BRCA2-mutated metastatic castrate-resistant prostate cancerChristopher T Su, Emily Nizialek, Jacob E Berchuck, et al.
JCO Precision Oncology|June 6, 2025
Cross-Comparison Individual Patient-Level Analysis of Three Gene Expression Signatures in Localized Prostate in Over 50,000 MenAngela Y Jia, Yilun Sun, Maitry Patel, et al.
European Urology Oncology|February 26, 2023
A Matching-adjusted Indirect Comparison of Nivolumab Plus Cabozantinib Versus Pembrolizumab Plus Axitinib in Patients with Advanced Renal Cell CarcinomaBradley McGregor, Daniel M Geynisman, Mauricio Burotto, et al.
Pageof 21